Approved Research

Genetic analysis and target identification for polygenic complex diseases

Lay summary

Our team from Bytedance is focusing on omics' data guided pharmaceutical development. We aim to target disease areas with high unmet needs and develop therapies to help these patients. We plan to use rich health record data, genetics data and plasma proteomics data from UK Biobank and conduct the following research. The project is expected to last 36 months.

  - Most diseases of high umet needs are polygenic common diseases. Genetic analysis is proven to be an effective method to understand underlying disease mechanisms of polygenic origin. We will perform genetic associations with multiple disease related traits in UKBB and identify genetic signals.

  - The nominated genes from above will be interpreted/validated further by proteomics and health record data within UKBB. We also intend to use other publicly available omics' datasets and develop knowledge graphs to enhance our understanding of disease mechanisms.